ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...
The overall prognosis for patients with high-grade glioma remains dismal, despite advances in treatment modalities including neurosurgery, radiation therapy and conventional cytotoxic chemotherapy. In ...
A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages that protect and nurture the brain tumor instead of attacking ...
Volume 11, Issue 28 of Oncotarget features "Genetic analysis of the cooperative tumorigenic effects of targeted deletions of tumor suppressors Rb1, Trp53, Men1, and Pten in neuroendocrine tumors in ...
Lin-Lu Tseng, Hsin-Hung Cheng, Ta-Sen Yeh, Shih-Chiang Huang, Ya-Yun Syu, Chih-Pin Chuu, Chiou-Hwa Yuh, Hsing-Jien Kung, Wen-Ching Wang Proceedings of the National Academy of Sciences of the United ...
Adding the investigational agent ipatasertib to paclitaxel failed to improve progression-free survival in patients with PIK3CA/AKT1/PTEN-altered advanced triple ...
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy A next-generation sequencing–based cfDNA assay was used to profile 231 patients with mCRPC from ...
A common genetic deficiency empowers glioblastoma to broadcast a molecular message to the wrong type of immune cell, summoning macrophages that protect and nurture the brain tumor instead of attacking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results